Skip to main content
  • Subscribe
  • Register
  • Sign in
  • Membership
  • Events
  • Knowledge Center
  • About
  • Subscribe
  • Register
  • Sign in
taub.png
Stephen Taub
Premium
AI Meets Biotech — and Hedge Funds Are Buying In
Caris Life Sciences’ IPO is backed by some of the industry’s biggest names as it pitches itself as a “next-gen TechBio” player.
Stephen Taub June 17, 2025
Getty Images

An innovative health care company that describes itself as a “next-generation AI TechBio company” is expected to go public this week. It has attracted a slew of hedge fund investors, including several of the most well-known firms.Caris Life Sciences plans to sell 23,529,412 shares for

To continue reading, subscribe now to Premium Journalism. Already a subscriber? login.


Contact Info

New York
1270 Avenue of the Americas, Suite 1100
New York, NY 10020
P: +1 212 224 3300

London
4 Bouverie Street
London EC4Y 8AX
P: +44 207 779 8888

Hong Kong
Unit 2488, 24/F
Lee Garden One,
33 Hysan Avenue
Causeway Bay, Hong Kong
P: +852 2912 8001

Corporate

About Us

Leadership Team

Careers

II Press Room

Digital

Masthead

Thought Leadership

Display Advertising

Reprints

FAQs

Events

Events Calendar

Memberships

Subscription

Subscribe to Premium

Register

Register for Free Account

Newsletters

Sign up for II newsletters

© 2025 Institutional Investor LLC. All material subject to strictly enforced copyright laws. Please read our Terms & Conditions, Modern Slavery Act Transparency Statement, Accessibility Statement and Privacy Policy before using the site.

LinkedIn
X
Bluesky

4.12.03 build:2025-12-12   Login